A password will be e-mailed to you.

United Greeneries plans to launch online retail sales of medical cannabis in February for Canadians covered by the Access to Cannabis for Medical Purposes Regulations — a program for which certain multiple sclerosis (MS) patients may be eligible. United Greeneries, a unit of Harvest One Cannabis, an umbrella company that also owns Switzerland’s Satipharm, has a medicinal cannabis cultivation and sales license. That allows Harvest One to not only sell but also commercially cultivate cannabis in a federally regulated environment. The company currently has more than 325 kilograms of dried cannabis in stock for immediate sale. According to a press release, the online platform will start by selling two cannabis brands — Captain’s Choice and Royal High — with plans to add Satipharm’s Gelpell Microgel capsules later on. Studies have shown that cannabis-derived therapeutic products can benefit MS patients. For example, researchers at the Washington-based National Academies of Sciences, Engineering, and Medicine concluded that certain cannabinoids can reduce spasticity symptoms in MS patients. Harvest One Plans Online Sales of Medical Cannabis for Canadians With MS

thumbnail courtesy of multiplesclerosisnewstoday.com